On the stock market since 2021, it operates in the world of health and science. It has 100 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 40% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
Sales run at $22.5M a year. A small number, but proof the product has real buyers.
There is $636.2M in the vault; even if every debt were paid off, $636.0M would remain.
The average analyst price target is $51.33 — 84% above today’s price.
A loss of $203.8M against $22.5M in annual sales. And on top of that, sales fell from the year before.
The sales tempo runs behind the sector. Council score: 2/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, NAMS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NAMS is a high-risk stock — not yet profitable, and its future rides on its product catching on.